ICIs	immune checkpoint inhibitors
MSI-H	microsatellite instability-high
FDA	The United States Food and Drug Administration
NSCLC	non-small cell lung cancer
EGFR-TKI	epidermal growth factor receptor-tyrosine kinase inhibitor
Tregs	regulatory T cells
LAG-3	lymphocyte activation gene-3
TIM-3	T cell immunoglobulin and mucin domain-3
Tight	T cell immunoglobulin and ITIM domain
PFS	progression-free survival
TME	tumor microenvironment
VEGF	vascular endothelial growth factor
HCC	hepatocellular carcinoma
OS	overall survival
mPFS	median PFS
mOS	median OS
RCC	renal cell carcinoma
mCRC	metastatic colorectal carcinoma
ORR	objective response rate
EGFR	epidermal growth factor receptor
HER2	human epidermal growth factor receptor 2
DOR	duration of response
T-DM1	trastuzumab emtansine
ADCs	antibody-drug conjugates
PARP	poly ADP-ribose polymerase
HRR	homologous recombination repair
HRD	homologous recombination deficiency
TMB	tumor mutation burden
TNBC	triple-negative breast cancer
TPS	tumor proportion score
AR	androgen receptor
ER	estrogen receptor
PR	progesterone receptor
HR+/HER2−	hormone receptor positive/HER2 negative
CDKs	cyclin-dependent kinases
ALK	anaplastic lymphoma kinase
CAR-T	Chimeric antigen receptor T cell
NK	Natural killer